222 related articles for article (PubMed ID: 31561525)
1. Marine Natural Products and Drug Resistance in Latent Tuberculosis.
Khan MT; Kaushik AC; Bhatti AI; Zhang YJ; Zhang S; Wei AJ; Malik SI; Wei DQ
Mar Drugs; 2019 Sep; 17(10):. PubMed ID: 31561525
[TBL] [Abstract][Full Text] [Related]
2. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
[TBL] [Abstract][Full Text] [Related]
4. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
Sengstake S; Bergval IL; Schuitema AR; de Beer JL; Phelan J; de Zwaan R; Clark TG; van Soolingen D; Anthony RM
BMC Infect Dis; 2017 Jul; 17(1):491. PubMed ID: 28697808
[TBL] [Abstract][Full Text] [Related]
5. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
[TBL] [Abstract][Full Text] [Related]
6. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.
Jagadeb M; Rath SN; Sonawane A
J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826
[TBL] [Abstract][Full Text] [Related]
7. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Bwalya P; Yamaguchi T; Mulundu G; Nakajima C; Mbulo G; Solo ES; Fukushima Y; Kasakwa K; Suzuki Y
Tuberculosis (Edinb); 2018 Mar; 109():117-122. PubMed ID: 29559115
[TBL] [Abstract][Full Text] [Related]
8. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
Ngabonziza JCS; Diallo AB; Tagliani E; Diarra B; Kadanga AE; Togo ACG; Thiam A; de Rijk WB; Alagna R; Houeto S; Ba F; Dagnra AY; Ivan E; Affolabi D; Schwoebel V; Trebucq A; de Jong BC; Rigouts L; Daneau G;
PLoS One; 2017; 12(10):e0187211. PubMed ID: 29088294
[TBL] [Abstract][Full Text] [Related]
9. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Masood N; Nadeem T; Khan AS; Afzal MT
BMC Infect Dis; 2019 Feb; 19(1):116. PubMed ID: 30728001
[TBL] [Abstract][Full Text] [Related]
10. Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960.
Maslov DA; Zaĭchikova MV; Chernousova LN; Shur KV; Bekker OB; Smirnova TG; Larionova EE; Andreevskaya SN; Zhang Y; Danilenko VN
Tuberculosis (Edinb); 2015 Sep; 95(5):608-12. PubMed ID: 26071666
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey].
Senol G; Coşkun M; Gündüz AT; Biçmen C; Gayaf M; Ozsöz A
Mikrobiyol Bul; 2008 Oct; 42(4):591-7. PubMed ID: 19149080
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
Xu P; Wu J; Yang C; Luo T; Shen X; Zhang Y; Nsofor CA; Zhu G; Gicquel B; Gao Q
Tuberculosis (Edinb); 2016 May; 98():56-61. PubMed ID: 27156619
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.
Njire M; Tan Y; Mugweru J; Wang C; Guo J; Yew W; Tan S; Zhang T
Adv Med Sci; 2016 Mar; 61(1):63-71. PubMed ID: 26521205
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
Stehr M; Elamin AA; Singh M
Expert Rev Anti Infect Ther; 2015 May; 13(5):593-603. PubMed ID: 25746054
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
17. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.
Hoffner S; Angeby K; Sturegård E; Jönsson B; Johansson A; Sellin M; Werngren J
Int J Tuberc Lung Dis; 2013 Nov; 17(11):1486-90. PubMed ID: 24125455
[TBL] [Abstract][Full Text] [Related]
18. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.
Salina EG; Ryabova O; Vocat A; Nikonenko B; Cole ST; Makarov V
J Infect Chemother; 2017 Nov; 23(11):794-797. PubMed ID: 28527650
[TBL] [Abstract][Full Text] [Related]
19. Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test.
Gokarn K; Pal RB
BMC Complement Altern Med; 2017 Mar; 17(1):161. PubMed ID: 28327117
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.
Liu W; Chen J; Shen Y; Jin J; Wu J; Sun F; Wu Y; Xie L; Zhang Y; Zhang W
Clin Microbiol Infect; 2018 Sep; 24(9):1016.e1-1016.e5. PubMed ID: 29288021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]